Niagara weight loss specialists at Fonthealth offer personalized weight management plans utilizing Zepbound® for patients in and around Niagara Region.
Zepbound® is a cutting-edge injectable medication approved for chronic weight management in adults with obesity or overweight conditions. It functions by activating GLP-1 and GIP receptors, which help reduce appetite and food intake, leading to significant weight loss when combined with a reduced-calorie diet and increased physical activity. Clinical trials have shown that patients on Zepbound® can achieve an average weight loss of up to 18% in non-diabetic adults, making it a highly effective option for long-term weight management and improving overall health.
Niagara weight loss specialists at Fonthealth offer Zepbound® as part of a comprehensive weight management program tailored to meet the unique needs of each patient. By integrating Zepbound® into personalized treatment plans, Fonthealth Weight Loss and Hormone Clinic helps Niagara patients achieve significant weight loss and manage related health conditions such as type 2 diabetes and hypertension.
Take the first step toward achieving your weight loss goals by calling Niagara weight loss practitioners at Fonthealth at (289) 294-0671 and learn how Zepbound® can be integrated into your personalized weight management plan today!
Benefits of Zepbound®
Zepbound® provides a comprehensive approach to weight management, leveraging its unique mechanism to offer multiple benefits that support long-term health and well-being. Key benefits include:
- Significant Weight Loss: Clinical trials have demonstrated that Zepbound® can lead to substantial weight reduction. Patients on the highest dose of 15 mg experienced an average weight loss of 18% in non-diabetic adults and 12% in those with type 2 diabetes over 72 weeks.
- Improved Blood Sugar Control: Zepbound® helps manage blood sugar levels in adults with type 2 diabetes, enhancing overall glucose control when combined with diet and exercise.
- Reduced Appetite: By activating GLP-1 and GIP receptors, Zepbound® decreases appetite, aiding in reduced food intake and supporting weight loss efforts.
- Decreased Risk of Weight-Related Conditions: Weight loss achieved with Zepbound® can lower the risk of developing serious conditions such as heart disease, stroke, and hypertension.
- Convenient Dosage Schedule: Zepbound® is administered once weekly via a subcutaneous injection, making it a convenient option for long-term weight management.
- Enhanced Quality of Life: By facilitating significant weight loss and improving overall health markers, Zepbound® contributes to better physical health and quality of life.
Zepbound® Procedure
Before starting Zepbound®
Before starting Zepbound®, Fonthealth will review your medical history, including any previous issues with your pancreas, kidneys, or severe stomach problems. They will also discuss potential interactions with other medications you are taking.
Using Zepbound®
Zepbound® is administered as a subcutaneous injection once a week. The initial dose is 2.5 mg, which is increased gradually, based on patient tolerance and response. The maximum dose is 15 mg weekly. Fonthealth will show you how to administer the injection, typically in the thigh, abdomen, or upper arm. It is important to rotate injection sites with each dose to avoid irritation.
Initially, you may be started on a lower dose, with increases occurring no more frequently than every four weeks. Regular follow-up visits will be scheduled with Fonthealth Weight Loss and Hormone Clinic to monitor your progress and adjust the dosage if necessary.
Injection Aftercare
After administering Zepbound®, you may experience some common side effects such as nausea, diarrhea, or injection site reactions. It is important to stay hydrated and follow any dietary recommendations provided by Fonthealth to minimize side effects.
Results of Zepbound®
Patients using Zepbound® can expect significant weight loss when combined with a reduced-calorie diet and increased physical activity. Clinical trials have shown that those on the highest dose of 15 mg experienced an average weight loss of 18% in non-diabetic adults and 12% in adults with type 2 diabetes over 72 weeks.
Health Benefits
- Weight Reduction: Substantial weight loss can reduce the risk of weight-related health conditions such as heart disease, stroke, and type 2 diabetes.
- Improved Metabolic Health: Along with weight loss, Zepbound® helps improve blood sugar control in patients with type 2 diabetes, contributing to overall metabolic health.
Long-Term Management:
Achieving and maintaining weight loss with Zepbound® requires ongoing commitment to a healthy lifestyle, including a balanced diet and regular physical activity. Continuous use of the medication, as prescribed by Fonthealth, along with regular medical follow-ups, will support long-term weight management and overall health improvement.
Zepbound® Frequently Asked Questions
What is Zepbound® and how does it work?
Zepbound® (tirzepatide) is an injectable prescription medication approved for chronic weight management in adults with obesity or overweight who have at least one weight-related medical condition. It works by activating GLP-1 and GIP receptors, which are hormones that help regulate appetite and food intake. This dual-action mechanism reduces hunger and increases feelings of fullness, supporting significant weight loss.
How is Zepbound® administered, and what is the recommended dosage?
Zepbound® is administered via a subcutaneous injection once weekly. The initial dose is typically 2.5 mg, which is gradually increased based on tolerance and efficacy, with the maximum dose being 15 mg weekly. It is important to follow Fonthealth‘s instructions and rotate injection sites to avoid irritation.
What are the common side effects of Zepbound®?
Common side effects of Zepbound® include nausea, diarrhea, vomiting, constipation, stomach pain, and injection site reactions. It is important to discuss any side effects with Fonthealth.
Who should not use Zepbound®?
Zepbound® should not be used by individuals with a personal or family history of medullary thyroid carcinoma, those with Multiple Endocrine Neoplasia syndrome type 2, or individuals who have had severe allergic reactions to tirzepatide. Additionally, it should not be used in combination with other tirzepatide-containing products or GLP-1 receptor agonists.
